Ads
related to: 5 azacitidine mechanism of action in leukemia- CML Treatment
Visit The Patient Website To
Learn More About This Treatment.
- Side Effects & Safety
Learn About Possible Side Effects
You May Experience During Treatment
- Connex Support
Patients, Find Support To Help You
During Your Treatment Journey.
- Side Effects On Treatment
Learn About Possible Side Effects
And Considerations With Treatment.
- Understanding CML
Patients With Ph+ CML-CP
Learn About A Treatment Option.
- Doctor Discussion Guide
Find The Patient Guide & Other
Helpful Resources Here.
- CML Treatment
Search results
Results From The WOW.Com Content Network
Azacitidine, sold under the brand name Vidaza among others, is a medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, [5] [6] and juvenile myelomonocytic leukemia. [ 4 ] [ 9 ] It is a chemical analog of cytidine , a nucleoside in DNA and RNA .
Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. [4] It is a medication for the treatment of myelodysplastic syndromes , a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). [ 5 ]
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
Demethylating agents and their relevance in clinical studies as therapy to treat lymphocytic leukemia can be seen in. [6] Procaine can also be used as therapeutic development to inhibit the growth of cancer cells in humans. There is a new world of possibilities of using demethylating agents to treat different diseases such as leukemia and ...
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
2.5 Histone deacetylase inhibitors: Panobinostat: add: add: add: add Romidepsin: IV: Histone deacetylase inhibitor, hence inducing alterations in gene expression in the affected cells. Peripheral and cutaneous T cell lymphoma. Electrolyte anomalies, anaemia, thrombocytopenia, neutropenia, lymphopenia and ECG anomalies. Valproate [Note 1] PO, IV ...
Ads
related to: 5 azacitidine mechanism of action in leukemia